SHTG Digest — Friday May 29, 2026

A quiet week on top-tier journal lipid papers, but four solid next-tier publications span plozasiran's approval story, a machine-learning breakthrough for predicting which HTG patients will develop pancreatitis, lipidomic signatures of drug-refractory HTG, and pediatric monogenic HTG genetics; on the industry side, Ionis's platform scores a landmark hepatitis B win this week, keeping the ASO powerhouse in the spotlight while its Tryngolza sHTG approval decision looms by June 30.